Feline IgG2 Antibody Stability via P113C and E111C Mutations
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Feline IgG2 antibodies are unstable, as indicated by extra bands on non-reduced sodium dodecyl sulfate polyacrylamide electrophoresis (nrSDS-PAGE) and non-reduced capillary gel electrophoresis (nrCGE), which affects their functionality and therapeutic efficacy.
Innovation Solution
A mutant feline IgG2 with amino acid substitutions at positions 113 (proline to cysteine, P113C) and 111 (glutamic acid to cysteine, E111C) is developed to enhance stability, resulting in a more stable antibody form.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If feline IgG2 is used as a therapeutic antibody, then it provides therapeutic function, but it exhibits instability under denaturing conditions
Solution Approach 1:
The patent applies parameter changes by substituting specific amino acid residues (P113C and E111C mutations) in the IgG2 constant region to alter the molecular structure and improve stability under denaturing conditions
Solution Approach 2:
The patent applies local quality by making targeted amino acid substitutions at specific positions (113 and 111) in the constant region rather than modifying the entire antibody structure, thereby locally improving stability while preserving overall function
2Stability of the object's composition
If amino acid substitutions are introduced to improve stability, then structural stability increases, but antibody complexity increases
Solution Approach 1:
The patent introduces minimal local changes (only two amino acid substitutions at positions 113 and 111) rather than comprehensive modifications, thereby improving stability while maintaining simplicity and avoiding excessive complexity
Data Source
AI summary
The invention relates generally to feline antibody variants and uses thereof. Specifically, the invention relates to mutations in the constant region of feline antibody for improving its stability.